Pfizer reports big jump in clinical trial success rate

Pfizer has reported (PDF) a sharp rise in its clinical trial success rate. The Big Pharma put its end-to-end success rate through 2020 at 21%, well up from the 9% it reported just last year.

Historically, Pfizer’s clinical research success rate has lagged behind those of its peers. In 2015, Pfizer calculated that just 5% of its assets that entered first-in-human studies went on to win approval, compared to an industrywide success rate of 11%. Pfizer reported an improvement at its investor day last year, claiming its success rate through 2019 was 9% versus an industry average of 8%.